Joint Formulary & PAD

Somapacitan - Growth failure - children

You are here : Home > Formulary Search > Somapacitan - Growth failure - children

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
ICB
NICE
SPC
Restrictions / Comments :
Important

To be initiated in patients <17yrs old as per NICE guidance.

Documentation

NICE Technology Appraisal
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (NICE TA1066)
Shared Care
Human Growth Hormone (Paed) Shared care Jul25.pdf
Evidence Review
Somapacitan for growth hormone deficiency TA1066 NICE briefing paper Jun25.pdf

PAD Profile

ChemicalSubstance :
Somapacitan
Indication :
Growth failure - children
Group Name :
Keywords :
Brand Names Include :
Sogroya
Important Information :

Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Committee Recommendations (1)

02 Jul 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves somapacitan for the treatment of growth hormone deficiency in people 3 to 17 years as recommended by NICE TA1066.

Somapacitan for this indication will be considered as AMBER - Prescribing initiated and stabilised by specialist team but has potential to transfer to primary care under a formal shared care agreement after 3 months of treatment.

Other Indications

Below are listed other indications that Somapacitan is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Growth failure - children.